Federated Hermes
SYRE icon

Federated Hermes’s Spyre Therapeutics SYRE Stock Holding History

Federated Hermes’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-77
Closed -$1K – 2280
2022
Q3 		$1K Hold
77
– – ﹤0.01% 2081
2022
Q2 		$1K Buy
+77
New +$2.7K ﹤0.01% 2081
2020
Q4 		– Sell
-15
Closed -$3K – 2325
2020
Q3 		$3K Hold
15
– – ﹤0.01% 2076
2020
Q2 		$3K Buy
+15
New +$2.86K ﹤0.01% 2059
2019
Q1 		– Sell
-20
Closed -$4K – 2228
2018
Q4 		$4K Sell
20
-32
-62% -$6.79K ﹤0.01% 2017
2018
Q3 		$12K Sell
52
-9
-15% -$2.1K ﹤0.01% 1928
2018
Q2 		$16K Buy
61
+30
+97% +$7.38K ﹤0.01% 1837
2018
Q1 		$8K Buy
+31
New +$5.6K ﹤0.01% 1911
2017
Q3 		– Sell
-10
Closed -$1K – 2190
2017
Q2 		$1K Buy
+10
New +$1.38K ﹤0.01% 2098

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Federated Hermes's SYRE Position: Q4 2022 in Review

Federated Hermes sold out of Spyre Therapeutics (SYRE) in Q4 2022, closing a stake of 77 shares — an estimated $1K sold.

Federated Hermes first reported a position in SYRE in Q2 2017 and held it in 9 quarters. The position peaked at $16K in Q2 2018. 50 funds tracked by Wall St. Rank hold SYRE as of Q4 2022.

  • Federated Hermes reported no remaining Spyre Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Federated Hermes sold 77 Spyre Therapeutics shares in Q4 2022, an estimated $1K.
  • Federated Hermes first reported a position in Spyre Therapeutics in Q2 2017 and held it in 9 quarters.
  • Federated Hermes's Spyre Therapeutics position peaked at $16K in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2022.

Based on Federated Hermes's 13F filing for Q4 2022, filed 13 Feb 2023.